AC Immune (NASDAQ:ACIU) Stock Rating Cut to “Hold” at Zacks Research

Zacks Research downgraded shares of AC Immune (NASDAQ:ACIU) from a strong-buy rating to a hold rating in a research note issued to investors on Wednesday morning,Zacks reports.

Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a report on Thursday, September 24th. Weiss Ratings downgraded shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.50.

AC Immune Price Performance

NASDAQ:ACIU opened at $2.37 on Wednesday. The company has a market capitalization of $241.20 million, a PE ratio of -4.39 and a beta of 1.56. AC Immune has a 52-week low of $2.03 and a 52-week high of $3.90. The stock’s 50 day moving average price is $2.62 and its 200 day moving average price is $2.74.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The company had revenue of $18.67 million for the quarter, compared to analyst estimates of $9.59 million. As a group, sell-side analysts anticipate that AC Immune will post -0.60 EPS for the current fiscal year.

Institutional Investors Weigh In On AC Immune

Several institutional investors and hedge funds have recently made changes to their positions in the business. AXQ Capital LP acquired a new stake in shares of AC Immune in the second quarter valued at approximately $25,000. Dimensional Fund Advisors LP increased its stake in shares of AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after purchasing an additional 30,035 shares in the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.